Hereditary Hemochromatosis: A Cardiac Perspective

Pranay K. Joshi, Saawan C. Patel, Devarashetty Shreya, Diana I. Zamora, Gautami S. Patel, Idan Grossmann, Kevin Rodriguez, Mirul Soni, Ibrahim Sange

Abstract

Hereditary hemochromatosis (HH) is a common genetic metabolic disorder characterized by excessive iron absorption and elevated serum iron levels, which accumulate in various organs, such as the heart, pancreas, gonads, and damage these organs. There are only a few articles and clinical studies describing the characteristics of cardiac involvement in HH along with the significance of early diagnosis and management in preventing complications. In this review article, we have reviewed multiple pieces of literature and gathered available information regarding the subject. We compiled the data to investigate the importance of early detection of symptoms, regular monitoring, and prompt management with strict adherence to reverse or prevent complications. This article has reviewed different aspects of cardiac hemochromatosis, such as pathogenesis, clinical presentation, diagnosis, and management. Recognition of early symptoms, diagnosis of cardiac involvement with various modalities, and implementation of early treatment are essentially the foundation of better outcomes in HH.

Introduction And Background

HH is an inherited, multi-systemic, progressive metabolic disease characterized by systemic iron overload and iron deposition in various visceral organs [1]. It is one of the most common inherited metabolic diseases worldwide and predominantly found among the Caucasian population with a frequency of the mutated gene C282Y found in one to two individuals in every 500 and less frequently found among Hispanics, Asians, and African Americans [2].

Historically, the first case of HH was described by French physician Armand Trousseau in the mid-19th century [3]. In 1935, Joseph Sheldon, a British geriatrician, described 311 case records in his monologue and concluded that hemochromatosis is an inherited disorder and resulted from the accumulation of iron in multiple organs [4]. Hemochromatosis was first linked to the HFE gene in 1996 by Feder et al.; 83% of patients were homozygous for missense mutation of HFE in the study [5]. Later on, multiple other genes were identified responsible for a minority of cases of HH such as hemojovelin (HJV), transferrin receptor 2 (TFR2), and ferroportin [6-8]. The genetic mutations that contribute to the pathogenesis of HH are multiple and have an expected outcome of excessive iron concentration in plasma.

The pathogenesis of HH involves the failure of the downregulation of iron metabolism. HFE-related hemochromatosis results from abnormally low levels of hepcidin, a key regulator of iron absorption from the duodenum, and the release of iron from the macrophage, secreted by the hepatocytes in response to decreasing plasma levels of iron [9]. The disorder can present with various symptoms, the most common being fatigue, malaise, and arthralgia [10]. In any individual with suspicion of HH, measurement of serum iron, ferritin, and transferrin saturation (TS) is recommended [11]. Management primarily involves the reduction of serum iron as well as total body iron by phlebotomy, as it has shown to slow the course of the disease, reverse organ damage, and prevent long-term complications [11-12]. Iron chelators are alternative therapy required in patients with anemia requiring chronic blood transfusion, unstable hemodynamic status, and a few refractory cases [13-14]. Heart failure and hepatic carcinoma are leading causes of mortality in HH, and approximately one-third of patients succumb to death as a result of cardiac causes [15-16]. The cardiac involvement in HH can have an insidious progression that eventually, over the course of the disease, leads to irreversible myocyte damage as the cells are overwhelmed by the deposition of iron, making the management of such cases challenging [17].

For reasons mentioned in the preceding paragraph, it is of paramount importance to detect cardiac...
Involvement in patients of HH at the earliest, with prompt initiation of treatment before the advent of complications.

In this article, we discuss the following aims and objectives: 1. Explore the early manifestations of cardiac hemochromatosis; 2. Emphasize the importance of early diagnosis of cardiac involvement; 3. Outline various modalities of management of cardiac hemochromatosis.

**Review**

**Iron metabolism and pathogenesis of cardiac hemochromatosis**

Iron has a substantial role in various biochemical reactions, and it is also the main component of biomolecules, such as hemoglobin and myoglobin, and multiple enzymes [18]. Furthermore, iron catalyzes oxidative reactions, which generate reactive oxygen species (ROS) [19-20]. Hence, excessive amounts of iron will lead to grave effects by generating excessive amounts of ROS, which mandates strict control of its level in the body. There is no specific pathway of iron excretion from the body except the losses that occur through the shedding of intestinal mucosal cells and menstruation in females [21]. Therefore, the most effective way to control the iron level in the body is through restricted absorption and not excretion.

Hepcidin controls the activity of ferroportin, an iron exporter present on the basolateral surface of enterocytes, macrophages, and hepatocytes (Figure 1) [22]. Although mechanisms and mediators responsible are different, all types of HH, in common, have abnormally low hepcidin levels. Reduced hepcidin level manifests as uninhibited activity of ferroportin and resultant excessive iron absorption, especially in classical HH [23]. More importantly, in classical HH, the macrophage plays a significant role than the duodenal enterocytes [23]. In patients of HH, macrophages release more iron than an average individual [24]. Irrespective of the clinical subtype, HH invariably involves dysfunctional iron metabolism. Usually, the body absorbs 1 to 2 mg iron daily; in HH, however, this reaches up to 8 to 10 mg per day [25]. Initially, transferrin saturation increases, which is the earliest biochemical marker of iron overload [26]. Gradually, as transferrin saturation reaches 75%, further iron remains in free form in the plasma, which has been termed non-transferrin-bound-iron (NTBI) and is central to the pathogenesis of HH, mainly through the generation of reactive oxygen species [19].
FIGURE 1: Schematic representation of iron metabolism and regulation

DMT-1: divalent metal transporter-1; TFR-2: transferrin receptor-2

HH can be divided into various subtypes (Table 1) [27].
| SUBTYPE | INHERITANCE | MUTATED GENE | SEVERITY | AGE OF ONSET | AFFECTED POPULATION | PHENOTYPE |
|---------|-------------|--------------|----------|--------------|---------------------|-----------|
| Type 1  | Autosomal   | HFE          | Mild     | 4-5 decade   | Middle-aged white male | Liver disease, Arthralgia, Fatigue |
|         | Recessive   |              |          |              |                     |           |
| Type 2  | Autosomal   | 2a: HJV      | Severe   | 1-2 decade   | Young, white/non-white, Male/female | Cirrhosis, Arrhythmia, Heart failure |
|         | Recessive   | 2B: HAMP     |          |              |                     |           |
| Type 3  | Autosomal   | tfr-2        | Mild to severe | 3-4 decade | Young, white/non-white, Male/female | Endocrinopathy, Cardiomyopathy, Liver failure |
|         | Recessive   |              |          |              |                     |           |
| Type 4  | Autosomal   | Ferroportin  | Mild     | 4-5 decade   | White/non-white, Male/female of all ages | Liver abnormalities, Marginal anemia, Hyperferritinemia |
|         | Dominant    |              |          |              |                     |           |

**TABLE 1: Clinical subtypes of hereditary hemochromatosis**

HAMP: hepcidin anti-microbial peptide; HJV: hemojovelin; tfr-2: transferrin receptor-2

Cardiac hemochromatosis is a common occurrence in patients of HH. It involves a multitude of presentations, which include but are not limited to cardiomyopathy, arrhythmia, and sudden cardiac death [28]. Gradually, in HH, as iron concentration builds up, the free iron eventually starts to accumulate in the heart. The free iron enters cardiomyocytes through the L-type calcium channel (LTCC) [29]. The free iron generates ROS through the Fenton reaction. It dramatically accelerates the production of hydroxyl ions, which damage the organelle membrane, cell membrane, and lysosomes, eventually leading to cell death in the heart [30]. Since cardiac myocytes have a high number of mitochondria and fewer antioxidants, they are particularly susceptible to damage from ROS [31]. All the subtypes have similar syndromic presentations because of identical pathogenesis and organ involvement. The only difference is the severity of the disease, with the juvenile form of HH involving the heart at an early stage with rapid deterioration [28]. Excess iron deposition begins from the epicardium and progresses towards the endocardium, which explains the preservation of ventricular systolic function till late in the disease [32]. In contrast to the previously held opinion that free iron gets deposited in the interstitial space, recent histological observations have shown that the iron is indeed deposited in the sarcoplasm [33]. Therefore, iron deposition in the heart is a form of storage rather than an infiltrative process, and potentially, it can be reversed with the initiation of appropriate therapy.

**Cardiac hemochromatosis: clinical presentation**

About 15% of HH patients have cardiac symptoms as a chief complaint. Symptoms appear insidiously and progress gradually, consisting of non-specific symptoms such as malaise, fatigue, and lethargy that worsen over time [28]. These symptoms are mainly the result of cardiomyopathy that can be either restrictive or dilated and has a progressive course that can result in death due to congestive heart failure if not treated promptly. Palpitations and sudden cardiac death occur due to iron deposition in the cardiac conduction system [34]. Udani et al. conducted a retrospective cohort study on 63,846,188 hospitalized patients to determine the prevalence and risk of CV manifestations in patients with hemochromatosis and discovered that among 64,590 patients with hemochromatosis, 27.8% had one or more cardiovascular manifestations [35]. Among CV manifestations, arrhythmias, congestive heart failure (CHF), and pulmonary hypertension were the most common [35].

Iron overload cardiomyopathy (IOC) can be either systolic or diastolic cardiac dysfunction originating from iron accumulation in cardiomyocytes, independent of other concomitant abnormalities such as ischemic cardiomyopathy, atherosclerosis, or valvular diseases [36]. IOC is a cardinal cause of mortality, especially in the second and third decades of life. In the long term, it has been called one of the most significant predictors of mortality in patients with iron overload [37]. IOC has common characteristics and progresses in a predictable way irrespective of the type of hemochromatosis, characterized by early restrictive cardiomyopathy (RCM) with diastolic dysfunction, which, if not treated in the early stage, invariably progresses to late dilated cardiomyopathy (DCM) with impaired systolic function (Figure 2) [38]. Oxidative stress in cardiomyocytes due to excessive free iron accumulation leads to impaired excitation-contraction coupling (ECC) and impaired function of sarcoplasmic reticulum calcium ATPase 2 (SERCA2) and sodium-calcium exchanger (NCX) channel leading to high intracellular calcium and sodium concentration, respectively [39-40]. These ionic changes within cardiomyocytes collectively lead to reduced peak systolic and high diastolic calcium levels, resulting in impaired systolic and diastolic function, respectively [41]. After entering into cardiomyocytes through L-type calcium channels, Fe+2 leads to the slowing of the Ca^2+ current resulting in high intracellular Ca^2+, which explains the early diastolic dysfunction [29]. Later on, with persistently elevated levels of Fe^2+, transport of Ca^2+ across the membrane is impaired because Fe^2+...
competes for the same iron transporter, which manifests as late systolic dysfunction seen in IOC [29]. Initially, patients have no overt symptoms but eventually, as diastolic dysfunction develops, non-specific symptoms such as mild to moderate exertional fatigue and exercise intolerance, appear [42]. Shizukuda et al. carried out a study on 43 asymptomatic HH patients with echocardiographic monitoring to evaluate the relationship between left ventricular diastolic function and oxidative stress and demonstrated a significant association between oxidative stress and left ventricular diastolic dysfunction in patients with HH in the early stage, with no overt symptoms and more than 55% ejection fraction (EF) [43]. Early in the disease, restrictive cardiomyopathy presents as diastolic heart failure with symptoms such as exertional dyspnea, exercise intolerance, orthopnea, peripheral swelling, and paroxysmal nocturnal dyspnea [44]. Later, untreated cases progress to irreversible dilated cardiomyopathy due to apoptosis of cardiomyocytes because of long-term iron deposition and subsequent damage by ROS. Dilated cardiomyopathy presents as systolic dysfunction and is often biventricular.

Rhythm abnormalities in cardiac hemochromatosis are common. Its etiopathogenesis involves iron deposition in the sinoatrial (SA) node, atrioventricular (AV) node, and cardiac conduction system [45]. In a clinical study undertaken by Shizukuda et al., 42 asymptomatic patients with homozygosity of C282Y showed no significant incidence of arrhythmia. Over six months, reducing iron levels in asymptomatic HH patients did not statistically reduce the incidence of arrhythmias [46]. They concluded that oxidative stress, rather than systemic iron-overload, is the main culprit behind arrhythmia in HH. After treatment with multiple phlebotomies, subjects have constantly elevated oxidative stress, which explains the persistence of arrhythmia in patients with near-normal serum iron levels [46]. These abnormalities include atrial tachyarrhythmias, premature ventricular beats, nodal block, and ventricular tachycardia, among which supraventricular arrhythmia is the most common cardiac rhythm disorder [16,47]. The iron itself is arrhythmogenic, as it can interfere with the cardiac conduction system [48]. Kenneth et al. conducted a study on the experimental animal model of IOC to determine the molecular and cellular mechanisms responsible for arrhythmia in subjects with iron overload. They hypothesized and demonstrated that iron-induced reduction in the sodium current is central to the pathogenesis of arrhythmia [49]; apart from this, they discovered fixed regions of conduction block that contribute to arrhythmia by establishing a re-entrant circuit [49]. Thus, action potential shortening and abnormal electrical impulse conduction due to heterogeneous iron deposition are essentially responsible for unidirectional block and arrhythmia in hemochromatosis [50]. Irregular rhythm may be due to atrial fibrillation, premature atrial contraction, or premature ventricular contractions. On the other hand, regular rhythm with rapid heart rate is due to atrial flutter, paroxysmal supraventricular tachycardia, or sustained ventricular tachycardia [50]. Symptoms may
Iron-chelators are used in refractory cases and patients with CHF. They increase the rate of iron excretion by echocardiographic findings showed a reduction in diameter and mass of LV in patients with abnormal LV management of HH demonstrated significant improvement in LV function after a long-term treatment study on 22 patients with HH carried out by Candell-Riera et al. to determine the efficacy of phlebotomy for serum iron levels. This frequency varies among patients depending on the iron reaccumulation rates maintenance treatment every two to three months is required with strict monitoring of hematocrit and levels below 30 ng/ml and transferrin saturation less than 30%. From tissues such as the heart, liver, and pancreas. The target of the therapy is to achieve serum ferritin twice, initially. Around 1 to 2 gm iron can be removed per month. This treatment helps to mobilize iron from tissues such as the heart, liver, and pancreas. The target of the therapy is to achieve serum ferritin levels below 30 ng/ml and transferrin saturation less than 30% After the target level is reached, maintenance treatment every two to three months is required with strict monitoring of hematocrit and serum iron levels. This frequency varies among patients depending on the iron reaccumulation rates. A study on 22 patients with HH carried out by Candell-Riera et al. to determine the efficacy of phlebotomy for management of HH demonstrated significant improvement in LV function after a long-term treatment. Echocardiographic findings showed a reduction in diameter and mass of LV in patients with abnormal LV parameters initially. Iron-chelators are used in refractory cases and patients with CHF. They increase the rate of iron excretion by
binding iron in plasma and tissue [64]. Deferoxamine, deferiprone, and deferasirox have been approved as iron-chelators. Deferoxamine is given subcutaneously or intravenously while the other two are delivered through the oral route. Intensive combination therapy with deferoxamine and deferiprone rapidly improves cardiac function to the normal state and reduces serum iron levels [65]. A new therapeutic approach includes calcium channel blockers (CCB). CCBs block iron uptake of cardiomyocytes through L-type calcium channels and prevent deposition of iron in the heart. An experimental study on mice demonstrated that amiodipine reduces iron uptake in the heart and reduces the amount of ROS generation [66]. It is imperative to initiate guideline-directed medical treatment (GDMT) for CHF, such as angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB), diuretics, beta-blockers, and inotropes, in patients who develop heart failure in the late stage of the disease. ACEI and ARB prevent remodeling of the heart and worsening of CHF. Beta-blockers decrease myocardial oxygen consumption and reduce mortality in the long term.

Limitations
This article solely focuses on cardiac abnormalities arising due to iron deposition in the heart and ignores other co-existing factors that can contribute to the modification of cardiac functions. Practically, many factors can influence cardiac functions, including environment, comorbidities, and genetic predisposition. The article has not considered disparities in the genetic structure of individuals that can result in certain people developing more severe and rapid cardiac dysfunction.

Conclusions
It is evident from the review article that, relatively, there are few studies regarding the emphasis on the early recognition and treatment of cardiac hemochromatosis. To summarize, HH can present as iron overload cardiomyopathy, arrhythmias, pulmonary hypertension, and CHF. IOC evolves predictably, beginning as RCM with diastolic dysfunction and, if left untreated, progresses to DCM with systolic dysfunction. CHF ensues as IOC progresses. Iron deposition in the heart generates ROS, damaging cardiomyocytes and triggering a cascade leading to impaired cardiac function. Diagnostic approaches to detect IOC are echocardiography, Doppler imaging, and cardiac MRI. Family members of patients should be screened for HH by genetic techniques. Cardiac function should be regularly monitored in asymptomatic patients and patients with symptoms other than cardiac. Cardiac hemochromatosis is best managed by therapeutic phlebotomy, and refractory cases are treated with iron chelators. The clinical implication of this article is to give a glance at various aspects of cardiac hemochromatosis. This article can serve as a shared resource to obtain knowledge, gain deep insight, and guide physicians to acquire additional information regarding the topic. Lastly, we feel that active investigation through clinical studies and systemic analysis is required to form a rigid construct and manage the condition more efficiently.

Additional Information

Disclosures

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Brissot P, Pietrangelo A, Adams PC, de Graaff B, McLaren CE, Lorelai O: Haemochromatosis. Nat Rev Dis Primers. 2018, 4:18016. 10.1038/nrdp.2018.16
2. Sikorska K, Bielawski KP, Romanowski T, Stalke P: Hereditary hemochromatosis: the most frequent inherited human disease [Article in Polish]. Postepy Hig Med Dosw (Online). 2006, 60:667-76.
3. Ulvik RJ: Hereditary haemochromatosis through 150 years. Tidsskr Nor Laegerforen. 2016, 153:2017-21. 10.4045/tidsskr.15.1003
4. Sheldon JH: Haemochromatosis. Lancet. 1954, 224:1051-6. 10.1016/S0140-6736(00)56615-X
5. Feder JN, Gniirke A, Thomas W, et al.: A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet. 1996, 15:399-408. 10.1038/ng099-399
6. Papaniokou G, Samuels ME, Ludwig EH, et al.: Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat Genet. 2004, 36:77-82. 10.1038/ng1274
7. Camaschella C, Roetto A, Call A, et al.: The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22. Nat Genet. 2000, 25:14-5. 10.1038/75534
8. Montosi G, Donovan A, Totoaro A, et al.: Autosomal-dominant hemochromatosis is associated with a mutation in the ferroportin (SLC11A5) gene. J Clin Invest. 2001, 108:619-25. 10.1172/JCI115468
9. Park CH, Valore EV, Waring AJ, Ganz T: Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem. 2001, 276:7806-10. 10.1074/jbc.M008922200
10. McDonnell SM, Preston BL, Jewell SA, et al.: A survey of 2,851 patients with hemochromatosis. Symptoms and response to treatment. Am J Med. 1999, 106:619-24. 10.1016/s0002-9343(99)00120-5
11. Adams PC, Barton JC, Guo H, Alter D, Speechley M: Serum ferritin is a biomarker for liver mortality in the hemochromatosis and iron overload screening study. Ann Hepatol. 2015, 14:548-53. 10.1016/S1665-2681(19)31274-8
Does oxidative stress modulate left ventricular diastolic function in asymptomatic subjects with hereditary hemochromatosis? Shizukuda Y, Bolan CD, Tripodi DJ, et al.: Lewis HP: overloading cardiomyopathy arrhythmogenesis of human siderotic heart disease Kuryshev YA, Brittenham GM, Fujioka H, Kannan P, Shieh CC, Cohen SA, Brown AM: 2017, 33:835-7. Hemochromatosis: implications for study and management of iron-overload cardiomyopathy Niederau C, Fischer R, Pürschel A, Stremmel W, Häussinger D, Strohmeyer G: 2010, 16:888-900. Iron overload cardiomyopathies: new insights into an old disease Liu P, Oliveri N: Iron overload cardiomyopathies: pathophysiology, diagnosis, and treatment. J Card Fail. 2010, 16:888-900. 10.1016/j.cardfail.2010.05.009 Niederau C, Fischer R, Sonnenberg A, Stremmel W, Trampisch HJ, Strohmeyer G: Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N Engl J Med. 1985, 313:1256-62. 10.1056/NEJM198511143151004 Kremastinos DT, Farmakis D: Iron overload cardiomyopathy in clinical practice. Circulation. 2011, 124:2253-63. 10.1161/CIRCULATIONAHA.111.052973 Zhabayev P, Oudit GY: Hemochromatosis protein (HFE) knockout mice as a novel model of hemochromatosis: implications for study and management of iron-overload cardiomyopathy. Can J Cardiol. 2017, 33:835-7. 10.1016/j.cjca.2017.04.013 Kuryshyev YA, Brittenham GM, Fujioka H, Kannan P, Shieh CC, Cohen SA, Brown AM: Decreased sodium and increased transient outward potassium currents in iron-loaded cardiac myocytes. Implications for the arrhythmogenicity of human siderotic heart disease. Circulation. 1999, 100:675-85. 10.1161/01.cir.100.6.675 Oudit GY, Trivieri MG, Kaper N, Liu PP, Backx PH: Role of L-type Ca2+ channels in iron transport and iron-overload cardiomyopathy. J Mol Med (Berl). 2006, 84:549-64. 10.1007/s00109-005-0029-x Lewis HP: Cardiac involvement in hemochromatosis. Trans Am Clin Climatol Assoc. 1954, 65:49-76. Shirzukuda Y, Bolan CD, Tripodi DJ, et al.: Does oxidative stress modulate left ventricular diastolic function in asymptomatic subjects with hereditary hemochromatosis? Echocardiography. 2009, 26:1155-8. 10.1111/j.1540-8175.2009.00956.x
44. Muhlestein JB: Cardiac abnormalities in hemochromatosis. hemochromatosis: genetics, pathophysiology, diagnosis, and treatment. Hemochromatosis: Genetics, Pathophysiology, Diagnosis and Treatment. James C. Barton, Corwin Q. Edwards (ed); Cambridge University Press, Cambridge, United Kingdom; 2000. 297-310.

45. Schwartz KA, Li Z, Schwartz DE, Cooper TG, Braselton WE: Earliest cardiac toxicity induced by iron overload selectively inhibits electrical conduction. J Appl Physiol (1985). 2002, 93:746-51. 10.1152/japplphysiol.01144.2001

46. Shizukuda Y, Tripodi DJ, Zalos G, et al.: Incidence of cardiac arrhythmias in asymptomatic hereditary hemochromatosis subjects with C282Y homozygosity. Am J Cardiol. 2012, 109:856-60. 10.1016/j.amjcard.2011.11.011

47. Dabestani A, Child JS, Perloff JK, Figueroa WG, Schelbert HB, Engel TR: Cardiac abnormalities in primary hemochromatosis. Ann N Y Acad Sci. 1988, 526:234-44. 10.1111/j.1749-6632.1988.tb55999.x

48. Wood JC, Enriquez C, Ghugre N, et al.: Physiology and pathophysiology of iron cardiomyopathy in thalassemia. Ann N Y Acad Sci. 2005, 1054:386-95. 10.1196/annals.1345.047

49. Laurita KR, Chuck ET, Yang T, et al.: Optical mapping reveals conduction slowing and impulse block in iron-overload cardiomyopathy. J Lab Clin Med. 2003, 142:83-9. 10.1016/j.jmlc.2003.04.006-X

50. Wu EC, Huang JW, Wu MS, et al.: The effect of iron stores on corrected QT dispersion in patients undergoing peritoneal dialysis. Am J Kidney Dis. 2004, 44:720-8. 10.1055/s-2004-826819

51. Shizukuda Y, Lingamaneni P, Rosing DR: Incidence of symptomatic arrhythmias and utilization of arrhythmia testing in 10-year follow up of cardiac asymptomatic hereditary hemochromatosis subjects. Am J Cardiol. 2021, 157:153-4. 10.1016/j.amjcard.2021.07.031

52. Vlahos AP, Koutoukou FP, Papamichael ND, et al.: Determinants of pulmonary hypertension in patients with beta-thalassemia major and normal ventricular function. Acta Haematol. 2012, 128:124-9. 10.1159/000328825

53. Gujja P, Rosing DR, Tripodi DJ, Shizukuda Y: Iron overload cardiomyopathy: better understanding of an increasing disorder. J Am Coll Cardiol. 2010, 56:1001-12. 10.1016/j.jacc.2010.03.083

54. Qaseem A, Aronson M, Fitterman N, Snow V, Weiss KB, Owens DK: Screening for hereditary hemochromatosis: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2005, 143:517-21. 10.7326/0003-4819-143-7-200510040-00010

55. Brownell A, Lowson S, Brozović M: Serum ferritin concentration in sickle cell crisis. J Clin Pathol. 1986, 39:235-5. 10.1136/jcp.39.3.235

56. Candell-Riera J, Liu L, Seres L, et al.: Cardiac hemochromatosis: beneficial effects of iron removal therapy. An echocardiographic study. Am J Cardiol. 1983, 52:824-9. 10.1016/0002-9149(83)90422-8

57. Shizukuda Y, Bolan CD, Tripodi DJ, et al.: Significance of left atrial contractile function in asymptomatic subjects with hereditary hemochromatosis. Am J Cardiol. 2006, 98:954-9. 10.1016/j.amjcard.2006.04.040

58. Palka P, Macdonald G, Lange A, Burstow DJ: The role of Doppler left ventricular filling indexes and Doppler tissue echocardiography in the assessment of cardiac involvement in hereditary hemochromatosis. J Am Soc Echocardiogr. 2002, 15:884-90. 10.1067/mje.2002.118052

59. Wood JC, Fassler JD, Meade T: Mimicking liver iron overload using liposomal ferritin preparations. Magn Reson Med. 2004, 51:607-11. 10.1002/mrm.10735

60. Pepe A, Postiano V, Santarelli MF, et al.: Multislice multiecho T2* cardiovascular magnetic resonance for detection of the heterogeneous distribution of myocardial iron overload. J Magn Reson Imaging. 2006, 23:662-8. 10.1002/mrm.20566

61. Porter JB: Practical management of iron overload. Br J Haematol. 2001, 115:239-52. 10.1046/j.1365-2141.2001.03195.x

62. Adams PC, Barton JC: How I treat hemochromatosis. Blood. 2010, 116:317-25. 10.1182/blood-2010-01-261875

63. Adams PC, Kertesz AE, Valberg LS: Rate of iron reaccumulation following iron depletion in hereditary hemochromatosis. Implications for venesection therapy. J Clin Gastroenterol. 1993, 16:207-10. 10.1097/00004836-199304000-00008

64. Glickstein H, El RB, Link G, et al.: Action of chelators in iron-loaded cardiac cells: accessibility to intracellular labile iron and functional consequences. Blood. 2006, 108:3195-203. 10.1182/blood-2006-05-020867

65. Farmaki K, Tsoumari I, Pappa C, Chouliaras G, Berdoukas V: Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. Br J Haematol. 2010, 148:666-75. 10.1111/j.1365-2141.2009.07970.x

66. Crowe S, Bartfay WI: Amlodipine decreases iron uptake and oxygen free radical production in the heart of chronically iron overloaded mice. Biol Res Nurs. 2002, 3:189-197. 10.1177/109980040200300404